Psychedelics May Treat Mental Health Problems Linked to COVID-19


According to the newspaper, Frontiers in Psychiatry, psychedelics may be the answer to tackling mental health issues from COVID-19.

The pandemic has impacted society in many ways, and people’s mental health is no exception.

However, all does not seem lost according to a team of Canadian researchers. Composed of people specializing in medicine, drug addiction and psychology, the team maintains that “Psychotherapy assisted by psychedelia” will be more effective in treating the symptoms of “PTSD, depression, anxiety, addictions and social disconnection”.

Photo: Getty Images

“As such, we would be remiss not to consider a new approach with anti-depressive, anxiolytic and anti-addictive potential that can also foster a sense of social and environmental connection,” the team wrote in their article.

Specifically, the team cited MDMA and psilocybin (found in magic mushrooms) as the drugs to use.

Both have been the subject of studies concerning “Treatment resistant” PTSD and depression.

According to the article, a study on psilocybin-assisted psychotherapy (published in the 2020 JAMA Psychiatry journal) found that he “Produces marked antidepressant effects in patients with [a] major depressive disorder: 71% had clinically significant reductions and 54% achieved remission 4 weeks later ”.

In other words, psychedelic treatment was much more effective in treating patients’ symptoms than psychotherapy alone.

At the same time, an MDMA-assisted psychotherapy experiment (published in 2021 Nature journal) found that “67% of the participants have not met anymore [the] clinical criteria for PTSD 2 months later » their treatment.

The results gave researchers confidence to propose that MDMA-assisted psychotherapy could be used to treat other “Trauma-related disorders”. These included “Social anxiety in adults with autism, anxiety / psychological distress at the end of life, alcohol use disorder and eating disorders”.


Ron Bauer – the founder of Theseus Capital, an investment firm that funds global science and technology-focused companies, agrees with Canadian researchers in an opinion piece for Newsweek:

“The ‘COVID generation’ could suffer throughout their lifetimes. We have a professional and personal duty to try everything to find new innovative treatments to reduce this burden and this effect on society as a whole. “

“[W]We need to stop treating psychedelics as illicit recreational drugs and start looking at them again the same way we did before the war on drugs started: seeing psychedelics as promising drugs with the potential to effectively treat a range of drugs. conditions and helping patients in need globally. “

“Conditions which I fear will be more prevalent than ever after the pandemic. “

According to the Black Dog Institute, it is estimated “Between 25% and 33% of [Australian] community was in a state of heightened anxiety “ due to the pandemic.

In addition to people with pre-existing conditions, the institute believes that healthcare workers, quarantined / unemployed people, and casual labor are at greater risk of developing mental health issues.

Source link

Leave A Reply

Your email address will not be published.